NCT00604383View on ClinicalTrials.gov

Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study

PHASE3CompletedINTERVENTIONAL
Enrollment

685

Participants

Timeline

Start Date

March 31, 2001

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Diabetic Retinopathy
Interventions
DRUG

ruboxistaurin

32-mg tablet, orally, daily, up to 42 months

DRUG

placebo

1 tablet, orally, daily, up to 42 months

Trial Locations (1)

Unknown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT -5 hours, EST) or speak with your personal physician., Indianapolis

All Listed Sponsors
lead

Chromaderm, Inc.

INDUSTRY

NCT00604383 - Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study | Biotech Hunter | Biotech Hunter